BioCryst Pharmaceuticals (NASDAQ:BCRX) is one of today's best performing low-priced stocks, up 9.8% to $1.80 on 1.3x average daily volume. BioCryst Pharmaceuticals has traded 837,000 shares thus far today, vs. average volume of 639,000 shares per day. The stock has outperformed the Dow (9.8% to the Dow's 0.1%) and outperformed the S&P 500 (9.8% to the S&P's -0.1%) during today's trading.

Over the past year, BioCryst Pharmaceuticals has traded in a range of $1.08 to $5.95 and is now at $1.80, 67% above that low. In the last five trading sessions, the 50-day moving average (MA) has fallen 11.8% while the 200-day MA has slid 2.1%.

BioCryst Pharmaceuticals has overhead space with shares priced $1.80, or 48.6% below the average consensus analyst price target of $3.50. The stock should hit resistance at its 200-day moving average (MA) of $3.44, as well as support at its 50-day MA of $1.69.

BioCryst Pharmaceuticals, Inc., a biopharmaceutical company, discovers and designs novel small-molecule pharmaceuticals using structure-based drug design. The Company's products are used for the treatment of immunological, viral, and cardiovascular diseases and disorders. BioCryst's lead immunological drug program targets T-cell proliferative disorders.

SmarTrend is tracking the current trend status for BioCryst Pharmaceuticals and will alert subscribers who have BCRX in their portfolio or watchlist when shares have changed trend direction.